Psoriasis oral therapy benchmarks have clustered around PASI 90 rates in the low-to-mid 50s for the leading approved pill, deucravacitinib — which makes envudeucitinib’s Phase 3 PASI 90 responses of 68.0% and 62.1% at Week 24 a genuinely disruptive number, not a marginal improvement. Alumis presented these figures from the ONWARD1 and ONWARD2 trials as a late-breaking oral at AAD 2026, and the data carry a design feature worth examining closely: quality-of-life improvements and itch relief preceded PASI 90 skin clearance in timing, and scalp clearance — historically one of the harder endpoints to move — appeared in roughly 30% of patients as early as Week 4. By Week 24, approximately three in four patients achieved clear or almost-clear scalp status. That sequence matters clinically because it suggests envudeucitinib’s TYK2 inhibition is hitting symptom burden before it fully resolves visible plaque, which is the inverse of what patients often endure through induction phases with biologics.
The trial design across ONWARD1 and ONWARD2 provides a durability signal that a single-study readout cannot. Both studies showed continued PASI response improvement between Week 16 and Week 24, meaning the drug was still accumulating efficacy at the later timepoint rather than plateauing early. That trajectory directly supports the NDA submission Alumis has targeted for Q4 2026, and the Q3 2026 ONWARD3 long-term data readout will be the first real test of whether those gains hold beyond six months — the window where oral therapies have historically shown erosion relative to biologics.
The SLE program adds a layer of strategic complexity. The LUMUS Phase 2b topline data, described as potentially pivotal, arrives in Q3 2026 — just ahead of the psoriasis NDA filing. A positive SLE readout would force a resource and regulatory sequencing question: can a company burning $81.5 million per quarter in R&D, with a cash runway extending only to Q4 2027, credibly run parallel NDA and BLA-track development without a partnership or capital raise? The decision to shelve lonigutamab rather than advance it suggests Alumis has already made hard prioritization choices.
The single number to track when LUMUS data land is not the headline response rate but the SLEDAI reduction depth at Week 24 — specifically whether envudeucitinib clears the threshold that would justify a Phase 3 design with a regulatory-grade primary endpoint rather than requiring a bridge study, which would push any SLE approval well past 2028 and materially change the cash math.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
